Allist(SH:688578) Shang Hai Zheng Quan Bao·2025-09-12 18:13Core Viewpoint - The announcement details a change in shareholder equity for Shanghai Ailis Pharmaceutical Technology Co., Ltd., indicating that certain shareholders have reduced their holdings, resulting in a decrease in their ownership percentage to below a significant threshold [4][5]. Group 1: Shareholder Information - The shareholders involved in the equity change are Shanghai Aixiang Enterprise Development Center (Limited Partnership) and Nantong Aiyun Enterprise Development Center (Limited Partnership), along with their concerted actions [3][4]. - The specific addresses of the shareholders are provided, indicating their locations in Shanghai and Jiangsu [3]. Group 2: Equity Change Details - From September 2 to September 12, 2025, the shareholders reduced their holdings by a total of 4,025,400 shares through block trading and centralized bidding, with Shanghai Aixiang reducing by 2,971,900 shares and Nantong Aiyun by 1,053,500 shares [4]. - Post-reduction, Shanghai Aixiang holds 25,727,034 shares (5.72% of total shares), while Nantong Aiyun holds 7,632,088 shares (1.70% of total shares) [4]. - The combined shareholding of the shareholders and their concerted actions decreased from 51.87% to 50.97%, crossing the 1% threshold [4]. Group 3: Additional Notes - The reduction in shares is part of a previously disclosed plan and does not trigger a mandatory tender offer, nor does it affect the control of the company or its governance structure [5]. - The shareholders have committed to adhering to relevant laws and regulations regarding further disclosures related to their shareholding changes [5].